Advertisement
Research Article

Use of Procalcitonin and C-Reactive Protein to Evaluate Vaccine Efficacy against Pneumonia

  • Shabir A Madhi mail,

    To whom correspondence should be addressed. E-mail: madhis@hivsa.com

    Affiliations: National Health Laboratory Service/University of the Witwatersrand/Medical Research Council Respiratory and Meningeal Pathogens Research Unit, University of the Witwatersrand, Johannesburg, South Africa, Paediatric Infectious Diseases Research Unit, Wits Health Consortium, University of the Witwatersrand, Johannesburg, South Africa

    X
  • Jayvant R Heera,

    Affiliations: National Health Laboratory Service/University of the Witwatersrand/Medical Research Council Respiratory and Meningeal Pathogens Research Unit, University of the Witwatersrand, Johannesburg, South Africa, Paediatric Infectious Diseases Research Unit, Wits Health Consortium, University of the Witwatersrand, Johannesburg, South Africa

    X
  • Locadiah Kuwanda,

    Affiliation: National Health Laboratory Service/University of the Witwatersrand/Medical Research Council Respiratory and Meningeal Pathogens Research Unit, University of the Witwatersrand, Johannesburg, South Africa

    X
  • Keith P Klugman

    Affiliations: National Health Laboratory Service/University of the Witwatersrand/Medical Research Council Respiratory and Meningeal Pathogens Research Unit, University of the Witwatersrand, Johannesburg, South Africa, Department of International Health, Rollins School of Public Health, and Division of Infectious Diseases, School of Medicine, Emory University, Atlanta, Georgia, United States of America

    X
  • Published: February 22, 2005
  • DOI: 10.1371/journal.pmed.0020038

About the Authors

Shabir A Madhi, Jayvant R Heera, Locadiah Kuwanda, Keith P Klugman
National Health Laboratory Service/University of the Witwatersrand/Medical Research Council Respiratory and Meningeal Pathogens Research Unit, University of the Witwatersrand, Johannesburg, South Africa
Shabir A Madhi, Jayvant R Heera
Paediatric Infectious Diseases Research Unit, Wits Health Consortium, University of the Witwatersrand, Johannesburg, South Africa
Keith P Klugman
Department of International Health, Rollins School of Public Health, and Division of Infectious Diseases, School of Medicine, Emory University, Atlanta, Georgia, United States of America

Corresponding Author

Email: madhis@hivsa.com

Competing Interests

The phase 3 study was supported by a grant from Wyeth-Lederle Vaccines and Pediatrics. SAM has received previous research support and consultancy fees from Wyeth Vaccines and Pediatrics. KPK has received previous research support and consultancy fees from Aventis, Bayer, GlaxoSmithKline, ID Biomedical, Oscient, Roche, and Wyeth-Ayerst.

Author Contributions

SAM, JRH, and KPK designed the study. SAM, JRH, LK, and KPK analyzed the data and contributed to writing the paper.